Navigation Links
Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
Date:3/13/2008

p> the period (59,357) (6,583) (65,940) 4,585 6,129 10,714

Basic net

(loss)

income per

common share

from

continuing

operations (0.56) (0.10) (0.66) 0.14 0.07 0.21

Diluted net

(loss) income

per common

share from

continuing

operations (0.56) (0.10) (0.66) 0.14 0.07 0.21

December 31, December 31,

2007 2006

---------------------------

a.) Royalty expense adjustments:

Reclassification of royalty expense

from selling, general and administrative - 577

Reclassification of royalty expense to

cost of products sold - (196)

------------- -------------

- 381

------------- -------------

b.) Cost of products sold adjustments:

Overvaluation of inventory in 2006 and

its reversal in 2007 (580) 580

Reclassification of royalty expense to

cost of products sold (note a) - 196

Net impact of fair value change of

inventory on acquisition - 700

------------- -------------

(580) 1,476

------------- -------------

c.) Selling, general and administrative

adjustments:

Stock-based compensation in 2006 an
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
2. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
3. Angiotech announces results for the fourth quarter ended December 31, 2007
4. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
6. Angiotech and Symphony Medical Announce Licensing Agreement
7. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech to participate in Bank of America 2007 Credit Conference
11. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Asia-Pacific , and Rest of ... 2012 through 2020. Market data and analytics are derived from ...
(Date:8/19/2014)... Aug. 19, 2014 Research ... of the "Spectroscopy Equipment and Accessories ... to their offering. This ... Equipment and Accessories in US$ Thousands by ... spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared ...
(Date:8/19/2014)... Md. , Aug. 19, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today that its novel ... at the 54 th Interscience Conference on ... Washington D.C. ...
(Date:8/18/2014)... Dallas, Texas (PRWEB) August 19, 2014 ... China Linalool Industryā€¯ is a professional and in-depth ... report provides basic Linalool information, including its ... well as industry overview. This research covers the ... well as global industry analysis covering macroeconomic environment ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4
... ANNAPOLIS, Md., May 7 /PRNewswire-FirstCall/ -- PharmAthene, ... company developing medical countermeasures against biological and chemical threats, ... quarter of 2009 will be released on Thursday, May ... to discuss its first quarter 2009 financial results. ...
... fuels provider New Generation Biofuels Holdings, Inc. (Nasdaq: ... has signed a contract with the City of Baltimore, Maryland,("the ... for boiler applications in the heart of Baltimore. This is ... non fossil fuel in its industrial boilers. In this program, ...
... May 7 Covance Inc. (NYSE: CVD ... its board of directors. Mr. McCartney currently serves as ... provider of specialty products, services, and supply chain solutions. ... of U.S. Robotics (USR), a multibillion dollar provider of ...
Cached Biology Technology:City of Baltimore to Evaluate New Generation Biofuels for Use in Boiler Applications 2City of Baltimore to Evaluate New Generation Biofuels for Use in Boiler Applications 3Covance Elects John McCartney to Company's Board of Directors 2
(Date:8/19/2014)... Plants are superior to humans and animals in a ... regenerate, which enables them to regrow entire organs. After ... grow back its entire crown. But there is one ... quite literally rooted to the habitats in which they ... elements. In response to this dilemma, plants have developed ...
(Date:8/19/2014)... to treat pain, but its effect on pain ... a recent study reported on the Neural ... rat models of an avulsion injury to the ... neuropathic pain) were given electroacupuncture stimulation at bilateral ... (GB34). After electroacupuncture therapy, chronic neuropathic pain in ...
(Date:8/19/2014)... news release is available in German . ... get new information about the metabolism of plants can ... However, Erich Kombrink from the Max Planck Institute for ... the University of Duisburg-Essen adopt a different approach. They ... metabolic process like brake pads and prevent the downstream ...
Breaking Biology News(10 mins):How steroid hormones enable plants to grow 2Researchers block plant hormone 2Researchers block plant hormone 3
... cases of Marburg haemorrhagic fever have been reported in ... reported its first 6 cases, bringing the number of ... part of the country. , Mobile surveillance teams in ... were attacked and damaged by local residents. As the ...
... provide a method of quantifying the expression and order of ... measure of cell physiology, said researchers at Baylor College of ... journal Nature Genetics. , "Microarray data are good phenotypes to ... measure of cell status," said Dr. Gad Shaulsky, associate professor ...
... administration to improve patient compliance and reduce drug side ... healthcare product category. While quietly gaining market share for ... and HRT, the technology is set to make further ... conditions wind their way through the development and clinical ...
Cached Biology News:WHO suspends Marburg work, appeals for new funds 2Microarrays as phenotype 2
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
MDMA Mouse Monoclonal Antibody (Clone 3G8)...
Biology Products: